Drug news
Medtronic to co promote Prolia (Amgen) in the US to spine specialists
Medtronic has agreed a three-year term to promote Prolia (denosumab) from Amgen to orthopedic and spine specialists in the US.
Prolia is approved in the US to treat postmenopausal women with Osteoporosis at high risk for fracture and to increase bone mass in men with osteoporosis at high risk for fracture.
Administered as a single subcutaneous injection of 60mg once every six months, Prolia is the first approved therapy that specifically targets an essential regulator of osteoclasts, RANK Ligand.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.